DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 14,322 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $149.86, for a total value of $2,146,294.92. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Kevin R. Sayer also recently made the following trade(s):
- On Tuesday, September 3rd, Kevin R. Sayer sold 10,000 shares of DexCom stock. The stock was sold at an average price of $170.13, for a total value of $1,701,300.00.
- On Thursday, August 15th, Kevin R. Sayer sold 10,000 shares of DexCom stock. The shares were sold at an average price of $156.12, for a total value of $1,561,200.00.
- On Monday, July 8th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The shares were sold at an average price of $146.25, for a total value of $877,500.00.
Shares of DXCM traded up $1.46 during midday trading on Wednesday, reaching $146.70. 911,812 shares of the company were exchanged, compared to its average volume of 1,200,108. The stock has a 50-day moving average price of $160.01 and a 200-day moving average price of $139.33. The company has a market cap of $13.26 billion, a price-to-earnings ratio of 489.00 and a beta of 0.72. DexCom, Inc. has a 1-year low of $105.05 and a 1-year high of $178.45. The company has a current ratio of 6.05, a quick ratio of 5.64 and a debt-to-equity ratio of 1.56.
DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.07. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The company had revenue of $336.40 million during the quarter, compared to the consensus estimate of $304.40 million. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The company’s revenue was up 38.7% compared to the same quarter last year. Equities research analysts anticipate that DexCom, Inc. will post 0.94 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its position in DexCom by 359.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,456,834 shares of the medical device company’s stock valued at $817,652,000 after buying an additional 4,268,926 shares during the last quarter. Jennison Associates LLC grew its stake in shares of DexCom by 211.2% during the second quarter. Jennison Associates LLC now owns 1,391,980 shares of the medical device company’s stock valued at $208,574,000 after acquiring an additional 944,642 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in shares of DexCom by 71.6% during the first quarter. Artisan Partners Limited Partnership now owns 1,164,081 shares of the medical device company’s stock valued at $138,642,000 after acquiring an additional 485,519 shares in the last quarter. Nuveen Asset Management LLC grew its stake in shares of DexCom by 1,781.3% during the second quarter. Nuveen Asset Management LLC now owns 1,107,735 shares of the medical device company’s stock valued at $165,983,000 after acquiring an additional 1,048,855 shares in the last quarter. Finally, Waddell & Reed Financial Inc. increased its position in shares of DexCom by 1.8% during the second quarter. Waddell & Reed Financial Inc. now owns 1,056,250 shares of the medical device company’s stock worth $158,269,000 after acquiring an additional 18,247 shares during the last quarter. 96.79% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have commented on DXCM shares. UBS Group upped their price target on DexCom from $140.00 to $160.00 and gave the stock a “neutral” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on DexCom from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Northland Securities reaffirmed a “hold” rating and issued a $125.00 price objective on shares of DexCom in a research note on Thursday, June 6th. Zacks Investment Research cut DexCom from a “buy” rating to a “hold” rating and set a $163.00 target price for the company. in a report on Monday, August 12th. Finally, BidaskClub downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. DexCom currently has an average rating of “Buy” and a consensus target price of $168.44.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: What are trading strategies for the 52-week high/low?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.